SEC Filing | Surmodics, Inc.

View:

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BEDOYA JOSE H

(Last)

(First)

(Middle)

604 10TH STREET

(Street)

BOULDER

80302

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
SURMODICS INC [ SRDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/20/2020		S		1,821	D	$37.5147⁽¹⁾	21,750⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reflects the weighted average price of 1,821 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on February 20, 2020 with sale prices ranging from $37.51 to $37.55 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

2. The amount beneficially owned includes 10,995 restricted stock units (RSUs) that vest on service-based vesting dates and 8,430 DSUs that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends.

Remarks:

	/s/ John Manders, on behalf of Jose H. Bedoya	02/24/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EXHIBIT 24
POWER OF ATTORNEY

		I, Jose H. Bedoya, hereby authorize and designate each of
 John Manders, Timothy Arens, Nicole J. Leimer, and Amra Hoso signing
 singly, as my true and lawful attorney-in-fact to:

	(1)	execute for and on my behalf, in my capacity as an officer and/or
 director of Surmodics, Inc., a Minnesota corporation (the "Company"), the
 Forms 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act
 of 1934 (the "Exchange Act") and the rules and regulations promulgated
 thereunder;

	(2)	do and perform any and all acts for and on my behalf which may be
 necessary or desirable to complete and execute any such Forms 4 or 5 and
 timely file such form with the Securities and Exchange Commission, any stock
 exchange or similar authority, and the NASDAQ Stock Market; and

	(3)	take any other action of any type whatsoever in connection with the
 foregoing which, in the opinion of such attorney-in-fact, may be to my
 benefit, in my best interest, or legally required of me, it being understood
 that the statements executed by such attorney-in-fact on my behalf pursuant to
 this Power of Attorney shall be in such form and shall contain such terms and
 conditions as such attorney-in-fact may approve in such attorney-in-fact's
 discretion.

		I hereby further grant to each such attorney-in-fact full power and
 authority to do and perform any and every act and thing whatsoever requisite,
 necessary, or proper to be done in the exercise of any of the rights and
 powers herein granted, as fully to all intents and purposes as I might or
 could do if personally present, with full power of substitutes or revocation,
 hereby ratifying and confirming all that such attorney-in-fact, or such
 attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
 done by virtue of this Power of Attorney and the rights and powers herein
 granted.  I hereby acknowledge that the foregoing attorneys-in-fact, in
 serving in such capacity at my request, are not assuming, nor is the Company
 assuming, any of my responsibilities to comply with Section 16 of the Exchange
 Act.

		This Power of Attorney shall remain in full force and effect until
 I am no longer required to file Forms 4 and 5 with respect to my holdings of
 and transactions in securities issued by the Company, unless earlier revoked
 by me in a signed writing delivered to the foregoing attorneys-in-fact.
  Notwithstanding the foregoing, if any such attorney-in-fact hereafter ceases
 to be either a partner or employee of Faegre Baker Daniels LLP, or an employee
 of the Company, this Power of Attorney shall be automatically revoked solely
 as to such individual, immediately upon such cessation, without any further
 action on my part.

		I hereby revoke all previous Powers of Attorney that have been
 granted by me in connection with my reporting obligations under Section 16 of
 the Exchange Act with respect to my holdings of and transactions in securities
 issued by the Company.

		IN WITNESS WHEREOF, I have caused this Power of Attorney to be duly
 executed as of this 12th day of February, 2020.

							/s/ Jose H. Bedoya